Niraparib in prostate cancer
Prostate Cancer

New Protocol: Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

2023-06-06

  • Study

    Double-blind, placebo-controlled phase 3 trial (MAGNITUDE)
    Previously untreated, CRPC
    Abirateron acetate + Niraparib (n=212) vs. Abiraterone acetate + PBO (n=211)

  • Efficacy

    BRCAmutated: mrPFS: 16.6 vs. 10.9 mos, HR:0.45, p=0.0003
    HRR +: mrPFS: 16.5 vs.13.7 mos, HR: 0.73, P=0.022
    HRR+ and nonBRCA: HR:0.99 [0.68-1.44] for rPFS

  • Safety

    Grade≥3 AEs: Anemia (29.7% vs. 28.0%), hypertension (14.6% vs. 12.3%), thrombocytopenia (6.6% vs. 2.4%)

    • J Clin Oncol 2023 41:18, 3339-3351

    Chi N. Kim et al. Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

    http://doi.org/10.1200/JCO.22.01649

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023